Press release
Metastatic Castration-Resistant Prostate Cancer Pipeline, Clinical Trials, Emerging Therapies and Companies 2024
Discover the latest drugs and treatment options in the Metastatic Castration-Resistant Prostate Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Metastatic Castration-Resistant Prostate Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Pipeline Report
* In September 2024:- Astellas Pharma- The purpose of this study was to evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in Chinese subjects with metastatic hormone sensitive prostate cancer (mHSPC). The study was conducted in two phases: Double-Blind treatment phase and open-label phase.
* In September 2024:- Bayer- The purpose of the study is to assess if the addition of darolutamide to ADT compared with ADT alone would result in superior clinical efficacy in participants with metastatic hormone-sensitive prostate cancer (mHSPC) by progression-free survival.
* In September 2024:-Janssen Research & Development, LLC- The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level < 0.2 nanograms/millilitres (ng/mL) after 6 months of treatment with apalutamide and ADT combination therapy provides non-inferior radiographic progression-free survival (rPFS) and a reduced burden of hot flashes measured as 18-month percent change in severity adjusted hot flash score.
* In September 2024:- AstraZeneca- The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
* In September 2024:- Pfizer- The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC.
* DelveInsight's Metastatic Castration-Resistant Prostate Cancer pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic Castration-Resistant Prostate Cancer treatment.
* The leading Metastatic Castration-Resistant Prostate Cancer Companies working in the market include Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen , and others.
* Promising Metastatic Castration-Resistant Prostate Cancer Therapies such as JNJ-78278343, Cetrelimab, Cabazitaxel, TVB-2640, Enzalutamide, Abiraterone acetate, JNJ-56021927, Xofigo (Radium-223 dichloride, BAY88-8223) , and others.
Stay ahead with the most recent pipeline outlook for Metastatic Castration-Resistant Prostate Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Metastatic Castration-Resistant Prostate Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Castration-Resistant Prostate Cancer Emerging Drugs Profile
* SRF617: Surface Oncology
SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39 in the tumor microenvironment, allowing for a dual mechanism of action to promote anti-tumor immunity via reduction of immunosuppressive adenosine in addition to increasing levels of immunostimulatory ATP. SRF617 has been granted Orphan Drug designation for the treatment of advanced pancreatic cancer by the FDA.
* Rucaparib: Clovis Oncology
Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway.
* HP518: Hinova Pharmaceuticals
HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.
Explore groundbreaking therapies and clinical trials in the Metastatic Castration-Resistant Prostate Cancer Pipeline. Access DelveInsight's detailed report now! @ New Metastatic Castration-Resistant Prostate Cancer Drugs [https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Castration Resistant Prostate cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Intravenous
* Subcutaneous
Metastatic Castration-Resistant Prostate Cancer Products have been categorized under various Molecule types such as
* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy
Unveil the future of Metastatic Castration-Resistant Prostate Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Metastatic Castration-Resistant Prostate Cancer Market Drivers and Barriers [https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Metastatic Castration-Resistant Prostate Cancer Pipeline Report
* Coverage- Global
* Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Metastatic Castration-Resistant Prostate Cancer Companies- Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
* Metastatic Castration-Resistant Prostate Cancer Therapies- JNJ-78278343, Cetrelimab, Cabazitaxel, TVB-2640, Enzalutamide, Abiraterone acetate, JNJ-56021927, Xofigo (Radium-223 dichloride, BAY88-8223), and others.
Get the latest on Metastatic Castration-Resistant Prostate Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Metastatic Castration-Resistant Prostate Cancer Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Metastatic Castration Resistant Prostate cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Metastatic Castration Resistant Prostate cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Rucaparib: Clovis Oncology
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Surface Oncology: SRF 617
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* REGN 4336: Regeneron Pharamceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* HP 518: Hinova Pharmaceuticals
* Drug profiles in the detailed report.....
* Inactive Products
* Metastatic Castration Resistant Prostate cancer Key Companies
* Metastatic Castration Resistant Prostate cancer Key Products
* Metastatic Castration Resistant Prostate cancer- Unmet Needs
* Metastatic Castration Resistant Prostate cancer- Market Drivers and Barriers
* Metastatic Castration Resistant Prostate cancer- Future Perspectives and Conclusion
* Metastatic Castration Resistant Prostate cancer Analyst Views
* Metastatic Castration Resistant Prostate cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-castrationresistant-prostate-cancer-pipeline-clinical-trials-emerging-therapies-and-companies-2024]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Castration-Resistant Prostate Cancer Pipeline, Clinical Trials, Emerging Therapies and Companies 2024 here
News-ID: 3681087 • Views: …
More Releases from ABNewswire
Multiple Sclerosis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Tri …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Multiple Sclerosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple Sclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Multiple Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
The Debut Album of Soldier'z of the Most High (S.O.T.M.H): The City in the Sky N …
From sourthern roots and legendary encounters to a new sound called Salvation Music, Chattanooga's own Freddy Mac delivers his long-awaited debut album.
Chattanooga, TN - The wait is over. Freddy Mac 2025 and his band Soldier'z of the Most High (S.O.T.M.H) proudly unveil their long-anticipated debut album, The City in the Sky. This groundbreaking project introduces Salvation Music [http://www.salvationmusic.com], a bold fusion of funk, metal, soul, and classical influences, brought to…
Author's Tranquility Press Announces the Heartwarming Release of Lil' Hal's Gian …
A Christmas Tale of Wonder, Patience, and Family Love That Shines Beyond the Wrapping Paper
Few things capture the spirit of Christmas like the thrill of a child discovering a gift under the tree. In Lil' Hal's Giant Christmas Box [https://www.amazon.com/Lil-Hals-Giant-Christmas-Box/dp/195754662X/ref=monarch_sidesheet_title] by Christy B., readers are invited into a magical holiday morning filled with suspense, laughter, and an unforgettable lesson: sometimes the greatest gifts require patience, faith, and love.
This beautifully illustrated…
"The Expedia of VoIP": Business Phone System Disrupts Carrier Model with Transpa …
Business owners can now shop multiple providers at once-choosing the right system without sales pressure or hidden fees.
Sheridan, Wyoming - Business Phone System, a vendor-neutral platform for business communications, today announced its official launch, offering business owners a smarter way to evaluate and select telecom services. Unlike traditional carriers that push their own packages, Business Phone System enables organizations to compare multiple providers side-by-side, ensuring the right solution is sized…
More Releases for Metastatic
Key Trends Reshaping the Metastatic Bone Disease Market: Advancements in Targete …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Metastatic Bone Disease Market Size Growth Forecast: What to Expect by 2025?
The market size for metastatic bone disease has seen a quick expansion in the past few years. This market will increase from a value of $17.14 billion in 2024 to $18.88 billion in 2025, with a compound…
Emerging Trends Influencing The Growth Of The Metastatic Urothelial Carcinoma Ma …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Metastatic Urothelial Carcinoma Market Size Expected to Be by 2034?
The market size for metastatic urothelial carcinoma has seen exponential growth recently. The market will expand from a worth of $1.18 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 20.2%.…
Key Influencer in the Metastatic Cancer Drugs Market 2025: Surging Prevalence Of …
How Are the key drivers contributing to the expansion of the metastatic cancer drugs market?
The escalation in the incidence of metastatic cancers will be a driving force for the expansion of the metastatic cancer drugs market. Metastatic cancer is a late-stage cancer that spreads across the body. As the number of metastatic cancer cases escalates, so does the creation of innovative drugs to treat various kinds of metastatic cancers. The…
Prominent Metastatic Breast Cancer Treatment Market Trend for 2025: Advancements …
Which drivers are expected to have the greatest impact on the over the metastatic breast cancer treatment market's growth?
The increasing occurrence of breast cancer is anticipated to boost the progression of the metastatic breast cancer treatment market. Breast cancer is a form of the disease that originates in the breast cells and is caused by abnormal cell growth in the breast, leading to the formation of a tumor. This alteration…
Major Force in the Metastatic Bone Disease Market 2025: Impact Of Bone Cancer Pr …
How Will the Metastatic Bone Disease Market Grow, and What Is the Projected Market Size?
The market size for metastatic bone disease has seen considerable growth in recent years. There is an expected increase from $17.14 billion in 2024 to $18.88 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The substantial growth during the historical period can be credited to factors like rising aging population, heightened cancer…
Combination Therapy Strategies for Metastatic Cancer
Metastatic cancer, where cancer cells spread from the primary tumor to distant organs, presents significant treatment challenges. Combination therapy strategies have emerged as a powerful approach to enhance treatment efficacy, overcome resistance, and improve patient outcomes in metastatic cancer.
Download Report:
https://www.kuickresearch.com/report-cancer-antibody-combinations-therapy-cancer-antibody-combination-monoclonal-antibodies-combination-drug-conjugate-antibodies-combination
One of the primary goals of combination therapy in metastatic cancer is to target both the primary tumor and metastatic sites. This comprehensive approach can improve overall disease control…
